2. Relieve the suffering: palliative care for the next decade.
作者: William E Rosa.;Stephen Connor.;Ghauri Aggarwal.;Samy Alsirafy.;Joanne Brennan.;Helena Davies.;Julia Downing.;Betty Ferrell.;Richard Harding.;Felicia Marie Knaul.;Emmanuel B K Luyirika.;María M Marroquín.;Joan Marston.;Lukas Radbruch.;M R Rajagopal.;Libby Sallnow.;Eric L Krakauer.
来源: Lancet. 2025年 3. Prolonged grief disorder.
作者: Clare Killikelly.;Kirsten V Smith.;Ningning Zhou.;Holly G Prigerson.;Mary-Frances O'Connor.;Cyrille Kossigan Kokou-Kpolou.;Paul A Boelen.;Andreas Maercker.
来源: Lancet. 2025年
Prolonged grief disorder is a mental health disorder recently included in diagnostic manuals worldwide. This Review presents published research evidence in strong support for the current conceptualisation of prolonged grief disorder: a diagnosable mental health condition with core symptoms of yearning, preoccupation, or both, which is associated with symptoms of emotional pain, identity disturbances, loss of meaning and purpose, and functional impairment. The public and academic discourse surrounding prolonged grief disorder has catalysed researchers to produce methodologically rigorous research evidence in support of this much-needed diagnosis. A coherent syndrome of prolonged grief disorder has a typical onset of 6 to 12 months after the death of a close person. Prolonged grief disorder is associated with various poor outcomes, including negative health outcomes (eg, high blood pressure), increased rates of suicidality, low life satisfaction, and increased service use. Psychotherapy is the main treatment for prolonged grief disorder. Theoretical models of the cause and maintenance of prolonged grief disorder are presently being refined through the rapidly increasing empirical literature. Awareness of prolonged grief disorder by general health practitioners, as well as mental health specialists, is key to appropriate early intervention.
17. Efficacy and safety of topical delgocitinib cream versus oral alitretinoin capsules in adults with severe chronic hand eczema (DELTA FORCE): a 24-week, randomised, head-to-head, phase 3 trial.
作者: Ana Maria Giménez-Arnau.;Andreas Pinter.;Wiebke Sondermann.;Ziad Reguiai.;Richard Woolf.;Charles Lynde.;Franz J Legat.;Antonio Costanzo.;Juan F Silvestre.;Natja Mellerup.;Marie Louise Østerdal.;Ursula Plohberger.;Lasse Ryttig.;Andrea Bauer.; .
来源: Lancet. 2025年
Chronic hand eczema is a heterogeneous, fluctuating, and long-lasting disease affecting the hands and wrists that substantially affects quality of life. For severe chronic hand eczema, topical corticosteroids are often unsatisfactory and systemic treatment can be required. The aim of the head-to-head, phase 3 DELTA FORCE trial was to evaluate the efficacy and safety of topical delgocitinib cream versus oral alitretinoin, the only currently approved systemic drug for severe chronic hand eczema.
19. Negative pressure wound therapy versus usual care in patients with surgical wound healing by secondary intention in the UK (SWHSI-2): an open-label, multicentre, parallel-group, randomised controlled trial.
作者: Catherine Arundel.;Laura Mandefield.;Caroline Fairhurst.;Kalpita Baird.;Athanasios Gkekas.;Pedro Saramago.;Ian Chetter.; .
来源: Lancet. 2025年
Surgical wound healing by secondary intention (SWHSI) presents a substantial management and financial challenge. Negative pressure wound therapy (NPWT) has increasingly been used as a treatment despite an absence of comparative evidence of effectiveness. We evaluated the effectiveness of NPWT compared with usual care for improving time to wound healing in patients with an SWHSI.
20. A proposed framework for monitoring and evaluating progress at the intersection of women, power, and cancer.
作者: Elise M Garton.;Gavin Allman.;Hyo Sook Bae.;Kalina Duncan.;Ibithal Fadhil.;Nazik Hammad.;Shirin Heidari.;Erica Liebermann.;Meritxell Mallafré-Larrosa.;Jennifer Moodley.;Rachel Nugent.;Isabelle Soerjomataram.;Carolyn D Taylor.;Karla Unger-Saldaña.;Verna Vanderpuye.;Ophira Ginsburg.
来源: Lancet. 2025年 |